DK3134084T3 - Fremgangsmåde til behandling af lungeadenokarcinom - Google Patents
Fremgangsmåde til behandling af lungeadenokarcinom Download PDFInfo
- Publication number
- DK3134084T3 DK3134084T3 DK15721100.4T DK15721100T DK3134084T3 DK 3134084 T3 DK3134084 T3 DK 3134084T3 DK 15721100 T DK15721100 T DK 15721100T DK 3134084 T3 DK3134084 T3 DK 3134084T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- pulmonary adenocarcinoma
- adenocarcinoma
- pulmonary
- Prior art date
Links
- 208000009956 adenocarcinoma Diseases 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984599P | 2014-04-25 | 2014-04-25 | |
| PCT/US2015/027800 WO2015164869A1 (en) | 2014-04-25 | 2015-04-27 | Method of treating lung adenocarcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3134084T3 true DK3134084T3 (da) | 2021-05-03 |
Family
ID=53055132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15721100.4T DK3134084T3 (da) | 2014-04-25 | 2015-04-27 | Fremgangsmåde til behandling af lungeadenokarcinom |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20170042880A1 (enExample) |
| EP (2) | EP3906921A1 (enExample) |
| JP (2) | JP6696908B2 (enExample) |
| KR (1) | KR102474701B1 (enExample) |
| CN (1) | CN106488768A (enExample) |
| AR (1) | AR100191A1 (enExample) |
| AU (1) | AU2015249232B2 (enExample) |
| BR (1) | BR112016024672A2 (enExample) |
| CA (1) | CA2946416C (enExample) |
| DK (1) | DK3134084T3 (enExample) |
| EA (1) | EA035223B1 (enExample) |
| ES (1) | ES2874875T3 (enExample) |
| HU (1) | HUE054557T2 (enExample) |
| IL (1) | IL248408B (enExample) |
| MX (1) | MX375716B (enExample) |
| PL (1) | PL3134084T3 (enExample) |
| PT (1) | PT3134084T (enExample) |
| SG (1) | SG11201608657QA (enExample) |
| TW (1) | TWI724988B (enExample) |
| UA (1) | UA121655C2 (enExample) |
| WO (1) | WO2015164869A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2704717A1 (en) | 2011-05-02 | 2014-03-12 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
| CN106255499A (zh) | 2014-03-17 | 2016-12-21 | 埃克塞里艾克西斯公司 | 卡博替尼制剂的给药 |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| MA40457A (fr) | 2014-08-05 | 2017-06-14 | Exelixis Inc | Combinaison de médicaments pour traiter le myélome multiple |
| US11141413B2 (en) | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| CN107353246A (zh) * | 2016-12-27 | 2017-11-17 | 辅仁药业集团熙德隆肿瘤药品有限公司 | 一种制备抗肿瘤药物卡博替尼的方法 |
| EP3631011B1 (en) * | 2017-05-31 | 2021-06-23 | Roche Diagnostics GmbH | Multiplex pcr detection of alk, ret, and ros fusions |
| US11504362B2 (en) | 2017-06-09 | 2022-11-22 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
| CN107541550A (zh) * | 2017-08-21 | 2018-01-05 | 上海派森诺生物科技股份有限公司 | 人ros1融合基因检测方法 |
| EP3685166A2 (en) * | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| SG11202006945PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AU2019212800B2 (en) * | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| DE102020005002A1 (de) * | 2020-08-17 | 2022-02-17 | Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh | Mittel zur Therapie von Tumorerkrankungen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5756696A (en) | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| US20100143918A1 (en) | 2007-01-19 | 2010-06-10 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| EP3072963B1 (en) | 2007-10-18 | 2020-04-01 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| TW201920110A (zh) * | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| SI2881402T1 (sl) | 2009-02-12 | 2017-12-29 | Cell Signaling Technology, Inc. | Ekspresija mutantnega ros pri humanem raku jeter |
| TWI585088B (zh) * | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| JP6513567B2 (ja) * | 2012-09-07 | 2019-05-15 | エクセリクシス， インク． | 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤 |
-
2015
- 2015-04-27 JP JP2016564236A patent/JP6696908B2/ja active Active
- 2015-04-27 IL IL248408A patent/IL248408B/en unknown
- 2015-04-27 CN CN201580022580.7A patent/CN106488768A/zh active Pending
- 2015-04-27 MX MX2016013600A patent/MX375716B/es active IP Right Grant
- 2015-04-27 PL PL15721100T patent/PL3134084T3/pl unknown
- 2015-04-27 CA CA2946416A patent/CA2946416C/en active Active
- 2015-04-27 AR ARP150101255A patent/AR100191A1/es unknown
- 2015-04-27 ES ES15721100T patent/ES2874875T3/es active Active
- 2015-04-27 WO PCT/US2015/027800 patent/WO2015164869A1/en not_active Ceased
- 2015-04-27 DK DK15721100.4T patent/DK3134084T3/da active
- 2015-04-27 EP EP21162169.3A patent/EP3906921A1/en not_active Withdrawn
- 2015-04-27 PT PT157211004T patent/PT3134084T/pt unknown
- 2015-04-27 US US15/305,854 patent/US20170042880A1/en not_active Abandoned
- 2015-04-27 TW TW104113427A patent/TWI724988B/zh active
- 2015-04-27 EA EA201692150A patent/EA035223B1/ru not_active IP Right Cessation
- 2015-04-27 UA UAA201611881A patent/UA121655C2/uk unknown
- 2015-04-27 EP EP15721100.4A patent/EP3134084B1/en not_active Revoked
- 2015-04-27 SG SG11201608657QA patent/SG11201608657QA/en unknown
- 2015-04-27 HU HUE15721100A patent/HUE054557T2/hu unknown
- 2015-04-27 KR KR1020167033010A patent/KR102474701B1/ko active Active
- 2015-04-27 BR BR112016024672-1A patent/BR112016024672A2/pt not_active Application Discontinuation
- 2015-04-27 AU AU2015249232A patent/AU2015249232B2/en active Active
-
2019
- 2019-07-05 JP JP2019126230A patent/JP2019189646A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR100191A1 (es) | 2016-09-14 |
| PL3134084T3 (pl) | 2021-09-27 |
| MX375716B (es) | 2025-03-06 |
| IL248408A0 (en) | 2016-11-30 |
| SG11201608657QA (en) | 2016-11-29 |
| EP3906921A1 (en) | 2021-11-10 |
| MX2016013600A (es) | 2017-04-27 |
| AU2015249232B2 (en) | 2020-06-25 |
| EP3134084B1 (en) | 2021-03-17 |
| HUE054557T2 (hu) | 2021-09-28 |
| CN106488768A (zh) | 2017-03-08 |
| WO2015164869A1 (en) | 2015-10-29 |
| JP2019189646A (ja) | 2019-10-31 |
| ES2874875T3 (es) | 2021-11-05 |
| PT3134084T (pt) | 2021-05-11 |
| KR102474701B1 (ko) | 2022-12-05 |
| EP3134084A1 (en) | 2017-03-01 |
| TWI724988B (zh) | 2021-04-21 |
| EA035223B1 (ru) | 2020-05-18 |
| JP2017513908A (ja) | 2017-06-01 |
| UA121655C2 (uk) | 2020-07-10 |
| IL248408B (en) | 2022-06-01 |
| NZ725576A (en) | 2021-03-26 |
| CA2946416A1 (en) | 2015-10-29 |
| JP6696908B2 (ja) | 2020-05-20 |
| BR112016024672A2 (pt) | 2021-02-02 |
| CA2946416C (en) | 2022-07-19 |
| US20170042880A1 (en) | 2017-02-16 |
| TW201622723A (zh) | 2016-07-01 |
| EA201692150A1 (ru) | 2017-02-28 |
| AU2015249232A1 (en) | 2016-11-10 |
| KR20160147934A (ko) | 2016-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249981A0 (en) | Method | |
| IL257252A (en) | Methods of treating fgf21-associated disorders | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| PL3325443T3 (pl) | Sposób otrzymywania pridopidyny | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3122444T3 (da) | Fremgangsmåde til fremstilling af membraner | |
| DK3231444T3 (da) | Ny behandling | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3341479T3 (da) | LNA-G-Proces | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3233071T3 (da) | Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| HUE057118T2 (hu) | Folyamat | |
| PL2907527T3 (pl) | Sposób eksploatacji urządzenia do napromieniania | |
| DK3191498T3 (da) | Fremgangsmåde til fremstilling af 2'-o-fucosyllactose | |
| DK3137449T3 (da) | Fremgangsmåder til fremstilling af substituerede cycloseriner | |
| DK3848028T5 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| IL252086A0 (en) | Novel methods |